Trial
NCT04344600
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Johns Hopkins University
Collaborators
Eiger BioPharmaceuticals
Condition
Sars-CoV-2 Infection
Intervention
Peginterferon lambda alfa-1a subcutaneous injection
Why stopped
Single center study with low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-14